Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL0020 Injection in EGFR-TKI–treated NSCLC Transformed to SCLC
CTR20260521Phase 2Active
- Sponsor
- Biling Bio
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL0020 in small cell lung cancer (SCLC), sponsored by Biling Bio. Started Feb 2026; status: active.
02
Drugs
BL0020
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20260521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260521.